Hangzhou Sciwind Biosciences Co., Ltd.
Clinical trials sponsored by Hangzhou Sciwind Biosciences Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could help shed pounds without needles Results expected Jan 2027 (estimated)
- New obesity drug XW003 takes on semaglutide in Head-to-Head trial Results expected Feb 2027 (estimated)
-
New obesity drug XW003 tested in teens – early results show promise
Disease control CompletedThis early-phase trial tested a new drug called XW003 in 48 Chinese teenagers with obesity. The main goal was to check safety and how the body processes the drug, while also tracking weight changes. Participants received either the drug or a placebo injection. Results will help d…
Phase 1 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New weekly shot could help control blood sugar in type 2 diabetes
Disease control CompletedThis study tested a new drug called ecnoglutide (XW003) in 211 adults with type 2 diabetes that was not well controlled by diet and exercise alone. Participants received either the drug or a placebo as a weekly injection for several weeks. The main goal was to see if the drug cou…
Phase 3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:54 UTC